Longeveron Inc.
LGVNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jul 29, 2024 | H.C. Wainwright | Raghuram Selvaraju | $10.00(+191%) | $3.44 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | downgrade | Buy →Hold | May 11, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 4, 2026 |
| Roth Capital | maintain | Buy | Aug 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 25, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 4, 2024 |
| Maxim Group | maintain | Buy | Aug 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 31, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 29, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 29, 2024 |
| EF Hutton | maintain | Buy | May 16, 2023 |
| EF Hutton | maintain | Buy | May 9, 2023 |
| EF Hutton | maintain | Buy | Mar 27, 2023 |
| EF Hutton | maintain | Buy | Jan 10, 2023 |
| Maxim Group | maintain | Buy | Mar 24, 2022 |
| EF Hutton | maintain | Buy | Jan 5, 2022 |
Earnings History
Next report: Mar 5, 2027 · EPS est. $-1.70| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-1.90 | $-1.75 | $287.0K | $326.0K |
| May 13, 2026 | $-0.19 | $-1.80 | $398.0K | $334.5K |
| Mar 17, 2026 | $-2.30 | $-4.20 | $365.0K | $110.3K |
| Nov 4, 2025 | $-0.39 | $-2.60 | $137.0K | $266.0K |
| Aug 13, 2025 | $-0.33 | $-0.35 | $316.0K | $419.0K |
| May 8, 2025 | $-0.34 | $-3.40 | $381.0K | $594.5K |
| Feb 28, 2025 | $-0.43 | $-3.60 | $603.0K | $634.0K |
| Nov 8, 2024 | $-3.40 | $-4.40 | $773.0K | $397.0K |
News
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the “Company”) (NASDAQ: LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company's financial advisor to explore potential strategic opportunities, including a potential business combination. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs.
ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association's (AHA) 2026 Scientific Sessions As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), a…
MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.
Longeveron on Wednesday said it would explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart condition.
Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability prof…
Longeveron to present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026; presentation 9/14/26 at 1:00pm ET
MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company's Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was pre…
Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company's executive leadership t…
Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript
On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty Three new independent D…
Longeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty MIAMI, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical-stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected from over 600 worldwide applicants to advan…